SOURCE: StockCall


November 10, 2010 09:07 ET

Equity Research on Akorn Inc. and AMAG Pharmaceuticals Inc. -- Diagnostic Substances Sector Sees Mixed Earnings Season so Far

JOHANNESBURG, SOUTH AFRICA--(Marketwire - November 10, 2010) - offers investors comprehensive research on the diagnostic substances industry and has completed analytical research on Akorn Inc. (NASDAQ: AKRX) and AMAG Pharmaceuticals Inc. (NASDAQ: AMAG). Register with us today at to have free access to these researches. 

The Diagnostic Substances sector has seen varied results across the board during this earnings season. Weakness in the economy and customer sentiment is posing challenges for some companies. Some companies have suffered from lower sample volumes and pricing pressures due to large amounts of competition. This decline has been offset other places by some doctors' new propensity to order more expensive genetic diagnostic tests. Register now at to have free access to our reports on the diagnostic substances industry. is an online platform where investors doing their due-diligence on the diagnostic substances industry can have easy and free access to our analyst research and opinions on Akorn Inc. and AMAG Pharmaceuticals Inc.; investors and shareholders of these companies can simply register for a complimentary membership at

In the DNA identity testing segment, companies saw higher revenues as United Kingdom forensic businesses increased their usage. Sales volumes for DNA based identity tests fell in the United States despite growth in government paternity tests. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Companies selling intravenous anemia treatments saw their sales increase during the quarter. One major issue for this portion of the sector is the FDA's current consideration towards strengthening the warning requirements accompanying the drugs to the most strict black box levels. There is some controversy over whether the company marketing this drug was misleading with its advertising.

For this quarter, Akorn Inc. saw its core revenues surge by 118% on the back of sustained growth of its newly released products and a rise in sales of antidote products. The company registered a net income of $4 million. Akorn Inc. research report is accessible for free by registering today at

Conversely, AMAG Pharmaceuticals Inc. posted a narrower loss as compared to the same quarter of 2009. Revenue on the other hand jumped to $16.9 million. AMAG Pharmaceuticals Inc. research report is available for free by signing up now at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information